Lir Life Sciences Corp. Formerly Blackbird Critical Metals Corp. Announces Closing of Acquisition of Lir Life Sciences Inc.

Executive Summary

• Lir Life Sciences Corp. completed the acquisition of all issued and outstanding shares of Lir Life Sciences Inc., issuing 22,312,678 post‑consolidated common shares to former Lir Inc. shareholders.
• Dr. Edward Mills was appointed Chief Executive Officer (and Director); additional senior appointments include CFO Harry Nijjar, and new directors Mark Dybul and Kevin May.
• The transaction was accompanied by a concurrent private placement raising $1.07 M and a debt conversion of $109,343, both resulting in additional common shares issued to the Company.

Key Details

• Acquisition Structure: 100% of Lir Inc. shares acquired; consideration – issuance of 22,312,678 post‑consolidated common shares of Lir Life Sciences Corp.
• Admin Fee Shares: 379,000 common shares issued to The Back Office Inc. as an administrative fee; subject to a statutory hold period of four months and one day.
• Management Changes:
• Dr. Edward Mills – appointed CEO & Director.
• Harry Nijjar – appointed CFO & Corporate Secretary.
• Mark Dybul – appointed Director.
• Kevin May – appointed Director.
• Resignations: Former directors Jason Riley, Norman Brewster, Jatinder Sandhar, and Gurdeep Bains resigned.
• Concurrent Financing (Oct 29 2025): Non‑brokered private placement of 3,050,270 subscription receipts at $0.35 each; gross proceeds $1,067,594.50. Each receipt converted to one Lir Inc. common share, then exchanged for Lir Life Sciences Corp. shares at closing.
• Debt Conversion: Settlement of $109,343 outstanding debt by issuing 312,408 Lir Inc. shares (deemed price $0.35 per share), subsequently exchanged for Lir Life Sciences Corp. shares at closing.
• Hold Periods: Securities issued in the concurrent financing and debt conversion subject to a voluntary four‑month hold period from closing date.
• Name Change: Effective Oct 31 2025, corporate name changed from “Blackbird Critical Metals Corp.” to “Lir Life Sciences Corp.”
• Trading Resumption: Common shares resumed trading on the Canadian Securities Exchange (CSE) under ticker “SKNY” on Nov 7 2025.

Notable Quotes

• “Dr. Edward Mills, Chief Executive Officer – ‘We are excited to complete this acquisition and advance our mission of delivering affordable obesity treatments through innovative transdermal technologies.’”